math cash flow dividend
provid detail remainco expect free cash flow
plan dividend transit exit upjohn
free cash flow look modest remainco immedi upjohn exit
gener annual oper cash flow ocf mid-teen billion
past year lyrica patent cliff upjohn exit impact
ocf cfo frank amelio state remainco gener pro forma
oper cash flow assum remainco dividend
payment current less estimate viatri dividend
sharehold remainco spend capital-expenditure yield remainco
initi annual free cash flow note expect remainco cash flow grow
meaning next five year driven high singl digit top-lin growth
cost effici expect share repurchas expect
util receiv part announc upjohn exit futur
dividend chang upjohn exit viatri complet said
sharehold remain whole current dividend expect
remainco stockhold retain viatri share
total pfizer dividend translat per share
full year per quarter base guidanc share
outstand annual dividend per share viatri portion
own total pfizer sharehold remain per share
remainco calcul
state viatri upjohn mylan divid per share
minimum dividend per share annual
viatri guidanc free cash flow
dividend free cash flow
viatri share count
remainco dividend per share could start annual slightli
lower viatri dividend slightli higher
share unaffect stock sharehold one share
remainco share viatri
major pharmaceut unit state america
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
share viatri could gener annual dividend note
mean viatri portion dividend pay-out would equat
base remainco share count
one share remainco could gener annual dividend
remainco higher pay-out ratio trend toward peer averag
time divid expect dividend per share ep
guidanc midpoint yield pay-out ratio peer
averag management target moder pay-out ratio
come year via strong ep growth estim doubl digit
modest annual dividend increas current assumpt rais
annual dividend
valuat methodolog risk
base case ep target multipl slight discount target peer
averag believ warrant due compound-annual-growth-rate revenu
ep growth in-lin peer group
risk upsid
upsid risk core busi upsid posit pipelin develop strateg
action creat sharehold valu multipl expand due improv growth
risk downsid
downsid risk financi shortfal price-to-earnings contract due pipelin shortfal
strateg action disappoint litig problem neg us drug
inform opinion research prepar co llc and/or and/or morgan
stanley mexico de bolsa de and/or canada limit use disclosur section includ morgan
stanley co llc mexico de bolsa de canada limit affili
necessari
import disclosur stock price chart equiti rate histori regard compani subject report pleas see morgan
stanley research disclosur websit www morganstanley com/researchdisclosur contact invest repres
research broadway attent research manag new york ny usa
valuat methodolog risk associ recommend rate price target referenc research report pleas contact client
support follow us/canada hong kong latin america london
singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
follow analyst herebi certifi view compani secur discuss report accur express
receiv receiv direct indirect compens exchang express specif recommend view report david
unless otherwis state individu list cover page report research analyst
morgan stanley research publish accord conflict manag polici avail
www morganstanley com/institutional/research/conflictpolici portugues version polici found www morganstanley com br
import us regulatori disclosur subject compani
decemb benefici own class common equiti secur follow compani cover
within last month manag co-manag public offer offer secur abbvi inc bristol-my squibb co
within last month receiv compens invest bank servic abbvi inc bristol-my squibb co
next month expect receiv intend seek compens invest bank servic abbvi inc bristol-my
within last month receiv compens product servic invest bank servic abbvi inc
within last month provid provid invest bank servic invest bank client relationship
follow compani abbvi inc bristol-my squibb co co merck co inc pfizer inc
within last month either provid provid non-invest bank securities-rel servic and/or past
enter agreement provid servic client relationship follow compani abbvi inc bristol-my squibb co co
employe director consult director merck co inc person research analyst member research
 co llc make market secur abbvi inc bristol-my squibb co co merck co inc pfizer inc
equiti research analyst strategist princip respons prepar research receiv compens base upon
variou factor includ qualiti research investor client feedback stock pick competit factor firm revenu overal invest bank
revenu equiti research analyst strategist compens link invest bank capit market transact perform morgan
stanley profit revenu particular trade desk
affili busi relat companies/instru cover research includ market make provid
liquid fund manag commerci bank extens credit invest servic invest bank sell buy
custom securities/instru compani cover research princip basi may posit debt
compani instrument discuss report trade may trade princip debt secur relat deriv
subject debt research report
certain disclosur list also complianc applic regul non-u jurisdict
use rel rate system use term overweight equal-weight not-rat underweight see definit morgan
stanley assign rate buy hold sell stock cover overweight equal-weight not-rat underweight equival
buy hold sell investor care read definit rate use morgan stanley research addit sinc morgan stanley research
contain complet inform concern analyst view investor care read morgan stanley research entireti infer
content rate alon case rate research use reli upon invest advic investor decis buy sell
stock depend individu circumst investor exist hold consider
decemb
stock rate describ appli fundament equiti research appli debt research produc firm
disclosur purpos accord nasd nyse requir includ categori head buy hold sell alongsid
rate overweight equal-weight not-rat underweight assign rate buy hold sell stock cover
overweight equal-weight not-rat underweight equival buy hold sell repres recommend rel weight see
definit satisfi regulatori requir correspond overweight posit stock rate buy recommend correspond
equal-weight not-rat hold underweight sell recommend respect
data includ common stock adr current assign rate invest bank client compani receiv invest
bank compens last month due round decim percentag provid total column may add exactli
overweight stock total return expect exceed averag total return analyst industri industri team coverag univers
risk-adjust basi next month
equal-weight stock total return expect line averag total return analyst industri industri team coverag univers
risk-adjust basi next month
not-rat nr current analyst adequ convict stock total return rel averag total return analyst
industri industri team coverag univers risk-adjust basi next month
underweight stock total return expect averag total return analyst industri industri team coverag univers
risk-adjust basi next month
unless otherwis specifi time frame price target includ morgan stanley research month
attract analyst expect perform industri coverag univers next month attract vs relev broad
market benchmark indic
in-lin analyst expect perform industri coverag univers next month line relev broad market
benchmark indic
cautiou analyst view perform industri coverag univers next month caution vs relev broad market
benchmark indic
benchmark region follow north america latin america relev countri index latin america index europ
europ japan topix asia relev countri index sub-region index ac asia pacif ex japan index
stock price price target rate histori rate definit
import disclosur morgan stanley smith barney llc custom
